Journal of Small Animal Practice 

About: Journal of Small Animal Practice is an academic journal published by Wiley-Blackwell. The journal publishes majorly in the area(s): Medicine & Population. It has an ISSN identifier of 0022-4510. Over the lifetime, 5678 publications have been published receiving 100211 citations. The journal is also known as: JSAP.

Infectious Diseases of the Dog and Cat

Abstract: Infectious Diseases of the Dog and Cat Craig E. Greene Published by Elsevier, 2006, 3rd edition, hardback, 1424 pages, Price £73.99, ISBN-10: 1416036008, ISBN-13: 978-1416036005

Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs.

Abstract: Neoplasia is common in pet dogs but accurate figures for the incidence of tumours in this, as in other species, are sparse. The purpose of this study was to document the occurrence of tumours in a defined population of dogs. From a database of 130,684 insured dogs, claims relating to the investigation or treatment of tumours or tumour-like lesions during a 12-month period were accessed and followed up. A total of 2,546 claims were tumour related and were classified according to tumour site and type. Because the demographics of the insured population were skewed towards younger animals, a standard population, as described in the veterinary literature, was used in the calculation of tumour incidence rates. The skin and soft tissues were the most common sites for tumour development, with a standardised incidence rate of 1,437 per 100,000 dogs per year, followed by alimentary (210), mammary (205), urogenital (139), lymphoid (134), endocrine (113) and oropharyngeal (112). Canine cutaneous histiocytoma was the most common single tumour type, with a standardised incidence rate of 337 per 100,000 dogs per year, followed by lipoma (318), adenoma (175), soft tissue sarcoma (142), mast cell tumour (129) and lymphosarcoma (114). These data are unique and provide a valuable basis for future research into the aetiology and epidemiology of canine tumours.

The prognosis following surgical removal of mastocytomas in dogs.

Abstract: Follow-up studies have been conducted on 114 dogs from which mastocytomas were removed surgically, and the subsequent progress of each animal recorded. To date, 38 % of animals have died or been destroyed as a direct consequence of the neoplastic process and of these, 69 % had histologically poorly-differentiated (Grade 1), 18% intermediate (Grade 2), and 13% well-differentiated (Grade 3) tumours. The mean survival time of animals with Grade 3 tumours was 51 weeks, whilst for those which had Grade 2 or Grade 1 types it was 28 and 18 weeks respectively. Most dogs which survive for longer than 30 weeks post-operatively appear to be cured, and on this basis the apparent cure rate for animals with Grade 3 tumours was six times greater than that for animals with Grade 1, and twice as great as that for animals with Grade 2 tumours. Although the best method of obtaining an accurate prognosis is to submit the excised tumour for histological examination, it can be said on clinical grounds alone that if a mastocytoma has been present for more than 28 weeks before removal, the prognosis should be favourable, since 83% of animals with this history survived for more than 30 weeks post-operatively. Resume. On a poirsuivi des recherches complementaires sur 114 chiens dont on a excise les mastocytomes. Les progres subsequents de chaque animal ont ete enregistres. Jusqu'a present, 38% des animaux sont morts ou ont ete detruits comme consequence directe du processus neoplastique, 69% de ces chiens avaient des tumeurs histologiquement assez mal differenciees (Grade 1), 18% des tumeurs intermediaires (Grade 2), et 13% des tumeurs bien differenciees (Grade 3). La periode moyenne de survie des animaux avec des tumeurs du grade 3 etait de 51 semaines tandis que pour ceux ayant des tumeurs des grades 2 et 1, cette periode etait de 28 et de 18 semaines respectivement. La plupart des chiens qui survivent plus de 30 semaines apres l'operation, semblent gueris et sur ce principe, le taux apparent de guerison pour des animaux avec des tumeurs du grade 3 etait de 6 fois superieure a celui pour des animaux avec des tumeurs du grade 1 et deux fois aussi eleve que celui pour des animaux avec des tumeurs du grade 2. Bien que la meilleure methode pour obtenir un prognostic correct soit de faire subir un examen histologique a la tumeur excisee, on peut dire, pour raison clinique seulement, que si un masto-cytome a ete present pendant plus de 28 semaines avant d'etre enleve, le prognostic devrait etre favorable, vu que 83% des animaux avec ce genre d'histoire ont survecu pendant plus de 30 semaines apres l'operation. Zusammenfassung. Nachuntersuchungen wurden an 114 Hunden ausgefuhrt an denen Mas-tozytome chirurgisch beseitigt wurden und folgenden Fortschritt verzeichnete man von jedem Tier. Bis heute, krepierten oder wurden vernichtet 38% der Tiere als direkte Folge der bosartigen Gewebeneubildung und von diesen hatten 69% histologisch schlecht zu unterscheidende Tumors (Grad 1), 18% zwischenliegende Tumors (Grad 2), und 13% gut zu unterscheidende Tumors (Grad 3). Die Durchschnitts-Uberlebungszeit von Tieren mit Grad 3 Tumors war 51 Wochen, wahrend fur jene mit Grad 2 und Grad 1 Typ es jeweilig 28 und 18 Wochen waren. Die meisten Hunde, die langer als 30 Wochen postoperativ uberleben, scheinen geheilt zu sein und aud dieser Basis war der offenbare Heilungsprozentsatz fur Tiere mit Grad 3 Tumors sechs mal grosser als der fur Tiere mit Grad 1 Tumors und zwei mal so gross als der mit Grad 2 Tumors. Obwohl die beste Methode eine akkurate Prognose zu erlangen ist den herausgeschnittenen Tumor histologischer Untersuchung zu unterwerfen, kann man durch klinische Erfahrung allein behaupten, wenn ein Mastozytom mehr as 28 Wochen vor der Entfernung vorhanden war, dass die Prognose gunstig sein musste, da 83% von Tieren mit dieser Krankheitsgeschichte mehr als 30 Wochen nachoperativ uberlebten.

Epidemiological study of blood pressure in domestic cats

Abstract: Previous experience has shown that a non-invasive (indirect) technique using an oscillometric monitor in conjunction with a tail cuff makes routine clinical blood pressure measurement practicable in dogs. The relationship between indirect and direct readings has been evaluated in both anaesthetised and conscious dogs (Bodey and others 1994, 1996). In this study, more than 2000 pressure measurements were taken from 1903 dogs. It was found that systolic is the most variable pressure parameter and that it depends on age, breed, sex, temperament, disease state, exercise regime and, to a minor extent, diet. Diet was not a significant determinant of diastolic and mean arterial pressure. Age and breed were the major predictors for all parameters. Heart rate was primarily affected by the temperament of the animal, though other factors also play a part in prediction. The distribution of systolic, diastolic, mean arterial pressure and heart rate across the dog population approximates to a log normal distribution. On the basis of these results it is possible to describe normal ranges for canine blood pressure; definition of hypertension, though, demands attention to age and breed normal values. The existence of statistically defined hypertension in an individual or breed does not imply adverse effects justifying therapy. Among the secondary causes of hypertension, such as diabetes, obesity and hyperadrenocorticism, hepatic disease was a new addition also undocumented in humans. The hypothesis that dogs, though classic model animals for hypertension, are resistant to its development found support from the modest increase in mean pressure values observed among dogs with renal disease, notably those with substantial reduction of glomerular filtration rate. The existence of breeds such as deerhounds with average pressures in the borderline range for hypertension in humans (and many individuals, therefore, well above) suggests that dogs may also be resistant to some of the adverse effects of high blood pressure.

Cardiac troponin I: evaluation of a biomarker for the diagnosis of heart disease in the dog

Abstract: Objectives: To assess the value of measuring blood levels of the myocardial protein cardiac troponin I (cTnI) in the diagnosis of congenital and acquired heart disease in the dog and in the evaluation of the severity of heart failure. Methods: Serum samples obtained from healthy dogs (n=26) and from dogs diagnosed with a variety of congenital and acquired heart conditions (n=35) were assayed for cTnI concentration using an automated immunoassay method. Results were also analysed according to the degree of heart failure as assessed using the International Small Animal Cardiac Health Council's scheme. Results: Healthy dogs had very low or undetectable blood cTnI levels, as did dogs with congenital heart disease. However, cTnI levels were significantly elevated in dogs with acquired mitral valve disease, dilated cardiomyopathy and pericardial effusion. Blood cTnI levels also varied with severity of heart failure. Clinical Significance: Measurement of blood cTnI levels may be a useful aid in the diagnosis of dogs with suspected heart disease and in indicating the severity of heart failure.